Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clara De Simone

Showing results (171-180 of 213) with videos related to

Pageof 22
Sort By:
Psoriasis (Auckland, N.Z.)|August 12, 2025
Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 yearsLuca Mastorino, Paolo Dapavo, Martina Burlando, et al.
International Journal of Dermatology|January 5, 2024
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohortRiccardo Viola, Luca Mastorino, Matteo Megna, et al.
Dermatology Practical & Conceptual|March 30, 2026
Effectiveness and Safety of Deucravacitinib in Moderate-to-Severe Psoriasis: an Italian Multicenter Real-Life Study in the Lazio RegionAnnunziata Dattola, Francesca Paola Sasso, Giorgio Marotta, et al.
The Journal of Dermatological Treatment|February 27, 2024
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study)Diego Orsini, Giacomo Caldarola, Annunziata Dattola, et al.
Journal of Clinical Medicine|July 13, 2024
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective StudyMarco Galluzzo, Emanuele Trovato, Marina Talamonti, et al.
Journal of the American Academy of Dermatology|May 22, 2026
Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: evidence from a prospective case-control study supporting ECD-BP180 ELISA in reducing diagnostic delayAnna Pira, Adele Salemme, Feliciana Mariotti, et al.
Therapeutic Advances in Chronic Disease|June 18, 2019
PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre studyMaria Sole Chimenti, Maria Esposito, Dario Graceffa, et al.
Dermatology Practical & Conceptual|March 21, 2025
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in ItalyFederico Pirro, Giacomo Caldarola, Nicoletta Bernardini, et al.
Clinical, Cosmetic and Investigational Dermatology|January 13, 2023
Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME StudyLuca Stingeni, Giovanna Malara, Andrea Conti, et al.
Dermatology Practical & Conceptual|April 14, 2025
Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio ExperienceAnnunziata Dattola, Nicoletta Bernardini, Elena Campione, et al.
Pageof 22

Showing results (171-180 of 213) with videos related to

Sort By:
Pageof 22
Psoriasis (Auckland, N.Z.)|August 12, 2025
Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 yearsLuca Mastorino, Paolo Dapavo, Martina Burlando, et al.
International Journal of Dermatology|January 5, 2024
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohortRiccardo Viola, Luca Mastorino, Matteo Megna, et al.
Dermatology Practical & Conceptual|March 30, 2026
Effectiveness and Safety of Deucravacitinib in Moderate-to-Severe Psoriasis: an Italian Multicenter Real-Life Study in the Lazio RegionAnnunziata Dattola, Francesca Paola Sasso, Giorgio Marotta, et al.
The Journal of Dermatological Treatment|February 27, 2024
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study)Diego Orsini, Giacomo Caldarola, Annunziata Dattola, et al.
Journal of Clinical Medicine|July 13, 2024
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective StudyMarco Galluzzo, Emanuele Trovato, Marina Talamonti, et al.
Journal of the American Academy of Dermatology|May 22, 2026
Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: evidence from a prospective case-control study supporting ECD-BP180 ELISA in reducing diagnostic delayAnna Pira, Adele Salemme, Feliciana Mariotti, et al.
Therapeutic Advances in Chronic Disease|June 18, 2019
PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre studyMaria Sole Chimenti, Maria Esposito, Dario Graceffa, et al.
Dermatology Practical & Conceptual|March 21, 2025
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in ItalyFederico Pirro, Giacomo Caldarola, Nicoletta Bernardini, et al.
Clinical, Cosmetic and Investigational Dermatology|January 13, 2023
Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME StudyLuca Stingeni, Giovanna Malara, Andrea Conti, et al.
Dermatology Practical & Conceptual|April 14, 2025
Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio ExperienceAnnunziata Dattola, Nicoletta Bernardini, Elena Campione, et al.
Pageof 22